Ad is loading...
APLS
Price
$30.08
Change
+$2.33 (+8.40%)
Updated
Nov 22, 03:14 PM (EDT)
102 days until earnings call
BCRX
Price
$7.61
Change
+$0.12 (+1.60%)
Updated
Nov 22, 03:16 PM (EDT)
89 days until earnings call
Ad is loading...

APLS vs BCRX

Header iconAPLS vs BCRX Comparison
Open Charts APLS vs BCRXBanner chart's image
Apellis Pharmaceuticals
Price$30.08
Change+$2.33 (+8.40%)
Volume$185
CapitalizationN/A
BioCryst Pharmaceuticals
Price$7.61
Change+$0.12 (+1.60%)
Volume$1.62K
CapitalizationN/A
APLS vs BCRX Comparison Chart
Loading...
APLS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
BCRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
APLS vs. BCRX commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLS is a Hold and BCRX is a Sell.

COMPARISON
Comparison
Nov 22, 2024
Stock price -- (APLS: $27.75 vs. BCRX: $7.49)
Brand notoriety: APLS: Not notable vs. BCRX: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLS: 44% vs. BCRX: 95%
Market capitalization -- APLS: $3.45B vs. BCRX: $1.51B
APLS [@Biotechnology] is valued at $3.45B. BCRX’s [@Biotechnology] market capitalization is $1.51B. The market cap for tickers in the [@Biotechnology] industry ranges from $463.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLS’s FA Score shows that 0 FA rating(s) are green whileBCRX’s FA Score has 1 green FA rating(s).

  • APLS’s FA Score: 0 green, 5 red.
  • BCRX’s FA Score: 1 green, 4 red.
According to our system of comparison, BCRX is a better buy in the long-term than APLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLS’s TA Score shows that 4 TA indicator(s) are bullish while BCRX’s TA Score has 3 bullish TA indicator(s).

  • APLS’s TA Score: 4 bullish, 4 bearish.
  • BCRX’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, APLS is a better buy in the short-term than BCRX.

Price Growth

APLS (@Biotechnology) experienced а -1.10% price change this week, while BCRX (@Biotechnology) price change was +0.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.14%. For the same industry, the average monthly price growth was -4.98%, and the average quarterly price growth was +4.01%.

Reported Earning Dates

APLS is expected to report earnings on Mar 04, 2025.

BCRX is expected to report earnings on Feb 19, 2025.

Industries' Descriptions

@Biotechnology (+2.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
APLS($3.45B) has a higher market cap than BCRX($1.51B). BCRX YTD gains are higher at: 25.042 vs. APLS (-53.642). BCRX has higher annual earnings (EBITDA): -24.12M vs. APLS (-209.71M). APLS has more cash in the bank: 397M vs. BCRX (330M). APLS has less debt than BCRX: APLS (470M) vs BCRX (809M). APLS has higher revenues than BCRX: APLS (715M) vs BCRX (413M).
APLSBCRXAPLS / BCRX
Capitalization3.45B1.51B228%
EBITDA-209.71M-24.12M870%
Gain YTD-53.64225.042-214%
P/E RatioN/AN/A-
Revenue715M413M173%
Total Cash397M330M120%
Total Debt470M809M58%
FUNDAMENTALS RATINGS
APLS vs BCRX: Fundamental Ratings
APLS
BCRX
OUTLOOK RATING
1..100
7467
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
3
Undervalued
PROFIT vs RISK RATING
1..100
10065
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
6449
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
9595

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCRX's Valuation (3) in the Biotechnology industry is significantly better than the same rating for APLS (74) in the Medical Distributors industry. This means that BCRX’s stock grew significantly faster than APLS’s over the last 12 months.

BCRX's Profit vs Risk Rating (65) in the Biotechnology industry is somewhat better than the same rating for APLS (100) in the Medical Distributors industry. This means that BCRX’s stock grew somewhat faster than APLS’s over the last 12 months.

APLS's SMR Rating (98) in the Medical Distributors industry is in the same range as BCRX (100) in the Biotechnology industry. This means that APLS’s stock grew similarly to BCRX’s over the last 12 months.

BCRX's Price Growth Rating (49) in the Biotechnology industry is in the same range as APLS (64) in the Medical Distributors industry. This means that BCRX’s stock grew similarly to APLS’s over the last 12 months.

BCRX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as APLS (100) in the Medical Distributors industry. This means that BCRX’s stock grew similarly to APLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APLSBCRX
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 19 days ago
85%
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
Bearish Trend 5 days ago
79%
Bearish Trend 8 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
80%
Aroon
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
83%
View a ticker or compare two or three
Ad is loading...
APLS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
BCRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EGFIX53.600.75
+1.42%
Edgewood Growth Instl
CVERX16.000.20
+1.27%
Columbia Select Mid Cap Value Instl 2
IRLUX43.400.19
+0.44%
Voya Russell Large Cap Index Port S2
MSGPX13.35N/A
N/A
Morgan Stanley Inst Glbl Infras R6
WEGRX13.76N/A
N/A
Allspring Emerging Growth R6

APLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, APLS has been loosely correlated with ZYME. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if APLS jumps, then ZYME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLS
1D Price
Change %
APLS100%
+0.95%
ZYME - APLS
39%
Loosely correlated
-5.98%
PGEN - APLS
38%
Loosely correlated
+7.91%
BCRX - APLS
36%
Loosely correlated
+2.60%
INZY - APLS
35%
Loosely correlated
-3.58%
IMVT - APLS
35%
Loosely correlated
+1.41%
More

BCRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCRX has been loosely correlated with PGEN. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if BCRX jumps, then PGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCRX
1D Price
Change %
BCRX100%
+2.60%
PGEN - BCRX
50%
Loosely correlated
+7.91%
VCYT - BCRX
46%
Loosely correlated
-0.66%
NKTX - BCRX
46%
Loosely correlated
-2.40%
NTLA - BCRX
43%
Loosely correlated
+5.18%
ATAI - BCRX
41%
Loosely correlated
-4.40%
More